Fibrinogen, red blood cells, and factor XIII in venous thrombosis

Journal of Thrombosis and Haemostasis

Volumn 13, Issue S1, 2015, Pages S208-S215

  Walton, B L ^a   Byrnes, J R ^a   Wolberg, A S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Clot retraction; Factor XIII; Fibrinogen; Platelet; Red blood cell; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 13; FIBRIN; FIBRINOGEN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

BLOOD RHEOLOGY; BLOOD VISCOSITY; CELL INTERACTION; DISEASE ASSOCIATION; ENZYME ACTIVITY; ERYTHROCYTE; FIBRIN FORMATION; FIBRINOGEN DEFECT; HUMAN; HYPERFIBRINOGENEMIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; VEIN THROMBOSIS; ANIMAL; BLOOD; BLOOD CLOTTING; CHEMISTRY; METABOLISM; PATHOPHYSIOLOGY; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD COAGULATION; ERYTHROCYTES; FACTOR XIII; FIBRIN; FIBRINOGEN; HUMANS; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; VENOUS THROMBOSIS;

EID: 84931400095     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12918     Document Type: Review

References (86)

1. Wolberg AS, Rosendaal FR, Weitz JI, Jaffer IH, Agnelli G, Baglin T, Mackman N. Venous thrombosis. Nat Rev Dis Pri 2015; 1: 15006. doi: 10.1038/nrdp.2015.6
2. Cines DB, Lebedeva T, Nagaswami C, Hayes V, Massefski W, Litvinov RI, Rauova L, Lowery TJ, Weisel JW. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood 2014; 123: 1596-603.
3. Aleman MM, Byrnes JR, Wang J-G, Tran R, Lam WA, Di Paola J, Mackman N, Degen JL, Flick MJ, Wolberg AS. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest 2014; 124: 3590-600.
4. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21: 131-42.
5. Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol 2011; 31: 494-9.
6. Collet JP, Shuman H, Ledger RE, Lee S, Weisel JW. The elasticity of an individual fibrin fiber in a clot. Proc Natl Acad Sci USA 2005; 102: 9133-7.
7. Liu W, Jawerth LM, Sparks EA, Falvo MR, Hantgan RR, Superfine R, Lord ST, Guthold M. Fibrin fibers have extraordinary extensibility and elasticity. Science 2006; 313: 634.
8. Liu W, Carlisle CR, Sparks EA, Guthold M. The mechanical properties of single fibrin fibers. J Thromb Haemost 2010; 8: 1030-6.
9. Hudson NE, Ding F, Bucay I, O'Brien ET 3rd, Gorkun OV, Superfine R, Lord ST, Dokholyan NV, Falvo MR. Submillisecond elastic recoil reveals molecular origins of fibrin fiber mechanics. Biophys J 2013; 104: 2671-80.
10. Carlisle CR, Sparks EA, Der Loughian C, Guthold M. Strength and failure of fibrin fiber branchpoints. J Thromb Haemost 2010; 8: 1135-8.
11. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-22.
12. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73: 151-61.
13. Austin H, Hooper WC, Lally C, Dilley A, Ellingsen D, Wideman C, Wenger NK, Rawlins P, Silva V, Evatt B. Venous thrombosis in relation to fibrinogen and factor VII genes among African-Americans. J Clin Epidemiol 2000; 53: 997-1001.
14. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
15. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 2003; 1: 2677-8.
16. Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, Hendrickson SB, Mosesson MW, Lord S, Weiler H. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood 2004; 103: 1728-34.
17. Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood 2011; 117: 4953-63.
18. Machlus KR, Lin F-C, Wolberg AS. Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice. Blood 2011; 118: 390-8.
19. Undas A, Podolec P, Zawilska K, Pieculewicz M, Jedlinski I, Stepien E, Konarska-Kuszewska E, Weglarz P, Duszynska M, Hanschke E, Przewlocki T, Tracz W. Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke 2009; 40: 1499-501.
20. Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydlowska A, Skubiszak A, Ciepluch K, Tracz W. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-8.
21. Martinez MR, Cuker A, Mills AM, Crichlow A, Lightfoot RT, Chernysh IN, Nagaswami C, Weisel JW, Ischiropoulos H. Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism. Am J Physiol Lung Cell Mol Physiol 2014; 306: L397-404.
22. Engesser L, Koopman J, de Munk G, Haverkate F, Novakova I, Verheijen JH, Briet E, Brommer EJ. Fibrinogen nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA. Thromb Haemost 1988; 60: 113-20.
23. Lijnen HR, Soria J, Soria C, Collen D, Caen JP. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 1984; 51: 108-9.
24. Fish RJ, Neerman-Arbez M. Fibrinogen gene regulation. Thromb Haemost 2012; 108: 419-26.
25. Rein-Smith CM, Anderson NW, Farrell DH. Differential regulation of fibrinogen gamma chain splice isoforms by interleukin-6. Thromb Res 2013; 131: 89-93.
26. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 2005; 106: 4176-83.
27. Nowak-Gottl U, Weiler H, Hernandez I, Thedieck S, Seehafer T, Schulte T, Stoll M. Fibrinogen alpha and gamma genes and factor V Leiden in children with thromboembolism: results from 2 family-based association studies. Blood 2009; 114: 1947-53.
28. Uitte de Willige S, Standeven KF, Philippou H, Ariëns RA. The pleiotropic role of the fibrinogen gamma' chain in hemostasis. Blood 2009; 114: 3994-4001.
29. Omarova F, Uitte De Willige S, Ariëns RA, Rosing J, Bertina RM, Castoldi E. Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen gamma'. J Thromb Haemost 2013; 11: 1669-78.
30. Omarova F, Uitte de Willige S, Simioni P, Ariëns RA, Bertina RM, Rosing J, Castoldi E. Fibrinogen gamma' increases the sensitivity to activated protein C in normal and factor V Leiden plasma. Blood 2014; 124: 1531-8.
31. Mosesson MW, Cooley BC, Hernandez I, Diorio JP, Weiler H. Thrombosis risk modification in transgenic mice containing the human fibrinogen thrombin-binding gamma' chain sequence. J Thromb Haemost 2009; 7: 102-10.
32. Lovely RS, Boshkov LK, Marzec UM, Hanson SR, Farrell DH. Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Br J Haematol 2007; 139: 494-503.
33. Walton BL, Getz TM, Bergmeier W, Lin F-C, Uitte de Willige S, Wolberg AS. The fibrinogen gamma A/gamma' isoform does not promote acute arterial thrombosis in mice. J Thromb Haemost 2014; 12: 680-9.
34. Maeda N, Seike M, Kume S, Takaku T, Shiga T. Fibrinogen-induced erythrocyte aggregation: erythrocyte-binding site in the fibrinogen molecule. Biochim Biophys Acta 1987; 904: 81-91.
35. Lominadze D, Dean WL. Involvement of fibrinogen specific binding in erythrocyte aggregation. FEBS Lett 2002; 517: 41-4.
36. Rampling MW. The binding of fibrinogen and fibrinogen degradation products to the erythrocyte membrane and its relationship to haemorheology. Acta Biol Med Ger 1981; 40: 373-8.
37. Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91: 931-72.
38. Katona E, Penzes K, Csapo A, Fazakas F, Udvardy ML, Bagoly Z, Orosz ZZ, Muszbek L. Interaction of factor XIII subunits. Blood 2014; 123: 1757-63.
39. Greenberg CS, Achyuthan KE, Fenton JW 2nd. Factor XIIIa formation promoted by complexing of alpha-thrombin, fibrin, and plasma factor XIII. Blood 1987; 69: 867-71.
40. Hornyak TJ, Shafer JA. Interactions of factor XIII with fibrin as substrate and cofactor. Biochemistry 1992; 31: 423-9.
41. Gersh KC, Lord ST. An investigation of factor XIII binding to recombinant γ'/γ' and γ/γ' fibrinogen. Blood 2006; 108: 485a.
42. Smith KA, Adamson PJ, Pease RJ, Brown JM, Balmforth AJ, Cordell PA, Ariëns RA, Philippou H, Grant PJ. Interactions between factor XIII and the alphaC region of fibrinogen. Blood 2011; 117: 3460-8.
43. Siebenlist KR, Mosesson MW. Progressive cross-linking of fibrin gamma-chains increases resistance to fibrinolysis. J Biol Chem 1994; 269: 28414-9.
44. Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through alpha-antiplasmin cross-linking. Blood 2011; 117: 6371-4.
45. Mitchell JL, Lionikiene AS, Fraser SR, Whyte CS, Booth NA, Mutch NJ. Functional factor XIII-A is exposed on the stimulated platelet surface. Blood 2014; 124: 3982-90.
46. Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77: 2813-26.
47. Hethershaw EL, Cilia La Corte AL, Duval C, Ali M, Grant PJ, Ariëns RA, Philippou H. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost 2014; 12: 197-205.
48. Glover CJ, McIntire LV, Brown CH 3rd, Natelson EA. Rheological properties of fibrin clots. Effects of fibrinogen concentration, factor XIII deficiency, and factor XIII inhibition. J Lab Clin Med 1975; 86: 644-56.
49. Ryan EA, Mockros LF, Stern AM, Lorand L. Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology. Biophys J 1999; 77: 2827-36.
50. Standeven KF, Carter AM, Grant PJ, Weisel JW, Chernysh I, Masova L, Lord ST, Ariëns RA. Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood 2007; 110: 902-7.
51. Helms CC, Ariëns RA, Uitte de Willige S, Standeven KF, Guthold M. Alpha-alpha cross-links increase fibrin fiber elasticity and stiffness. Biophys J 2012; 102: 168-75.
52. Duval C, Allan P, Connell SD, Ridger VC, Philippou H, Ariëns RA. Roles of fibrin alpha- and gamma-chain specific cross-linking by FXIIIa in fibrin structure and function. Thromb Haemost 2014; 111: 842-50.
53. Bereczky Z, Muszbek L. Factor XIII and venous thromboembolism. Semin Thromb Hemost 2011; 37: 305-14.
54. Wartiovaara U, Mikkola H, Szoke G, Haramura G, Karpati L, Balogh I, Lassila R, Muszbek L, Palotie A. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost 2000; 84: 595-600.
55. Balogh I, Szoke G, Karpati L, Wartiovaara U, Katona E, Komaromi I, Haramura G, Pfliegler G, Mikkola H, Muszbek L. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 2000; 96: 2479-86.
56. Ariëns RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
57. Lim BC, Ariëns RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-31.
58. Ho CH. The hemostatic effect of packed red cell transfusion in patients with anemia. Transfusion 1998; 38: 1011-4.
59. Dicato M. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. Oncologist 2008; 13(Suppl. 3): 11-5.
60. Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Hansen JB. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. Haematologica 2010; 95: 270-5.
61. Eischer L, Tscholl V, Heinze G, Traby L, Kyrle PA, Eichinger S. Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study. PLoS ONE 2012; 7: e38705.
62. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368: 22-33.
63. Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, Hooper WC. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 2007; 110: 908-12.
64. Atici AG, Kayhan S, Aydin D, Yilmaz YA. Plasma viscosity levels in pulmonary thromboembolism. Clin Hemorheol Microcirc 2013; 55: 313-20.
65. Ben-Ami R, Barshtein G, Mardi T, Deutch V, Elkayam O, Yedgar S, Berliner S. A synergistic effect of albumin and fibrinogen on immunoglobulin-induced red blood cell aggregation. Am J Physiol Heart Circ Physiol 2003; 285: H2663-9.
66. Carvalho FA, Connell S, Miltenberger-Miltenyi G, Pereira SV, Tavares A, Ariëns RA, Santos NC. Atomic force microscopy-based molecular recognition of a fibrinogen receptor on human erythrocytes. ACS Nano 2010; 4: 4609-20.
67. De Oliveira S, Vitorino de Almeida V, Calado A, Rosario HS, Saldanha C. Integrin-associated protein (CD47) is a putative mediator for soluble fibrinogen interaction with human red blood cells membrane. Biochim Biophys Acta 2012; 1818: 481-90.
68. Hermand P, Huet M, Callebaut I, Gane P, Ihanus E, Gahmberg CG, Cartron JP, Bailly P. Binding sites of leukocyte beta 2 integrins (LFA-1, Mac-1) on the human ICAM-4/LW blood group protein. J Biol Chem 2000; 275: 26002-10.
69. Ihanus E, Uotila L, Toivanen A, Stefanidakis M, Bailly P, Cartron JP, Gahmberg CG. Characterization of ICAM-4 binding to the I domains of the CD11a/CD18 and CD11b/CD18 leukocyte integrins. Eur J Biochem 2003; 270: 1710-23.
70. Hermand P, Gane P, Huet M, Jallu V, Kaplan C, Sonneborn HH, Cartron JP, Bailly P. Red cell ICAM-4 is a novel ligand for platelet-activated alphaIIbbeta3 integrin. J Biol Chem 2003; 278: 4892-8.
71. Spring FA, Parsons SF, Ortlepp S, Olsson ML, Sessions R, Brady RL, Anstee DJ. Intercellular adhesion molecule-4 binds alpha(4)beta(1) and alpha(V)-family integrins through novel integrin-binding mechanisms. Blood 2001; 98: 458-66.
72. Barr JD, Chauhan AK, Schaeffer GV, Hansen JK, Motto DG. Red blood cells mediate the onset of thrombosis in the ferric chloride murine model. Blood 2013; 121: 3733-41.
73. An X, Schulz VP, Li J, Wu K, Liu J, Xue F, Hu J, Mohandas N, Gallagher PG. Global transcriptome analyses of human and murine terminal erythroid differentiation. Blood 2014; 123: 3466-77.
74. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood 2001; 98: 3228-33.
75. Peyrou V, Lormeau JC, Herault JP, Gaich C, Pfliegger AM, Herbert JM. Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost 1999; 81: 400-6.
76. Horne MK 3rd, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red blood cells on thrombin generation. Br J Haematol 2006; 133: 403-8.
77. Whelihan MF, Zachary V, Orfeo T, Mann KG. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood 2012; 120: 3837-45.
78. van der Meijden PE, van Schilfgaarde M, van Oerle R, Renne T, ten Cate H, Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012; 10: 1355-62.
79. Jy W, Johansen ME, Bidot C Jr, Horstman LL, Ahn YS. Red cell-derived microparticles (RMP) as haemostatic agent. Thromb Haemost 2013; 110: 751-60.
80. Zecher D, Cumpelik A, Schifferli JA. Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement. Arterioscler Thromb Vasc Biol 2014; 34: 313-20.
81. Gersh KC, Nagaswami C, Weisel JW. Fibrin network structure and clot mechanical properties are altered by incorporation of erythrocytes. Thromb Haemost 2009; 102: 1169-75.
82. Wohner N, Sotonyi P, Machovich R, Szabo L, Tenekedjiev K, Silva MM, Longstaff C, Kolev K. Lytic resistance of fibrin containing red blood cells. Arterioscler Thromb Vasc Biol 2011; 31: 2306-13.
83. van Gelder JM, Nair CH, Dhall DP. Erythrocyte aggregation and erythrocyte deformability modify the permeability of erythrocyte enriched fibrin network. Thromb Res 1996; 82: 33-42.
84. Liang XM, Han SJ, Reems JA, Gao D, Sniadecki NJ. Platelet retraction force measurements using flexible post force sensors. Lab Chip 2010; 10: 991-8.
85. Wufsus AR, Rana K, Brown A, Dorgan JR, Liberatore MW, Neeves KB. Elastic behavior and platelet retraction in low- and high-density fibrin gels. Biophys J 2015; 108: 173-83.
86. Sutton JT, Ivancevich NM, Perrin SR Jr, Vela DC, Holland CK. Clot retraction affects the extent of ultrasound-enhanced thrombolysis in an ex vivo porcine thrombosis model. Ultrasound Med Biol 2013; 39: 813-24.